|
|
CGAMP |
|
Vaxjo ID |
297 |
|
Vaccine Adjuvant Name |
CGAMP |
|
Alternative Names |
cyclic GMP-AMP |
|
Adjuvant VO ID |
VO_0005591
|
|
Description |
novel adjuvant produced by binding of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) to DNA sequence that produces a mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
cyclic GMP-AMP dinucleotide, which comprises a 2'-5' and a 3'-5' phosphodiester linkage |
|
Function |
innate immune activation, Directly binds to STING to induce the production of type I IFN and inflammatory cytokines. |
| References |
Li et al., 2013: Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science (New York, N.Y.). 2013; 341(6152); 1390-1394. [PubMed: 23989956].
Yan and Chen, 2021: Yan H, Chen W. The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development. Vaccines. 2021; 9(8); . [PubMed: 34452042].
Zhu et al., 2022: Zhu W, Wei L, Dong C, Wang Y, Kim J, Ma Y, Gonzalez GX, Wang BZ. cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice. Molecular therapy. Nucleic acids. 2022; 30; 421-437. [PubMed: 36420215].
|
|
